New York, NY – Imagenomix Corp., a leader in AI-driven precision medicine, is excited to announce a groundbreaking partnership with Alterome Therapeutics Inc., a pioneering oncology drug development company. This collaboration will leverage Imagenomix’s cutting-edge artificial intelligence technologies to optimize clinical trial efficiency, improve patient stratification, and accelerate the development of Alterome’s targeted cancer therapies.
The partnership represents a convergence of Imagenomix’s advanced AI expertise with Alterome’s innovative approach to precision oncology. Together, the companies aim to set a new standard for using AI to transform clinical trials and deliver life-saving treatments to patients faster.
Travis Wold, CEO of Imagenomix Corp., emphasized the transformative potential of the partnership:
“We are honored to collaborate with Alterome Therapeutics Inc., a trailblazer in precision oncology. At Imagenomix, we are committed to leveraging AI to advance medicine, and this partnership exemplifies the extraordinary impact of combining state-of-the-art technology with innovative therapeutic development.”
Dr. Andrew Chi, Chief Medical Officer of Alterome Therapeutics Inc., shared his perspective on the collaboration:
“We are excited to integrate Imagenomix’s AI-powered analytics into our clinical trials., Together, we have an opportunity to redefine the way precision oncology clinical trials are conducted. By developing methods to rapidly identify critical patient selection biomarkers with unparalleled efficiency and scale we can potentially pave a new path to faster, more effective precision oncology trials. This approach could easily translate into routine patient care and ultimately improve patient outcomes.”
Key Highlights of the Partnership:
- Accelerated Drug Development: The Imagenomix Predict AI platform will streamline clinical trial timelines and improve cost-effectiveness.
- Enhanced Precision: Advanced analytics aims to identify critical biomarkers with unprecedented speed, scale, and efficiency to ensure targeted patient selection for Alterome’s targeted therapy trials.
- Industry Innovation: The partnership represents a paradigm shift in leveraging AI for oncology clinical trials, setting a new benchmark for the field.
This strategic collaboration underscores the shared commitment of Imagenomix Corp. and Alterome Therapeutics Inc. to harness the power of innovative technologies in delivering precision medicine breakthroughs.
For more information, visit:
- Imagenomix Corp.: www.imagenomix.ai
- Alterome Therapeutics Inc.: www.alterome.com